Docket No. MCP-5016 NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David Wynn et al.

Serial No. : 10/608,681 Art Unit:

Filed : June 27, 2003 Examiner:

For : SOFT TABLET CONTAINING HIGH MOLECULAR WEIGHT

CELLULOSICS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

September A2, 2003
(Date of Deposit)

Michele G. Mangini
(Name of applicant, assignee, or Registered Representative)

September 23, 2003

Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

(Date of Signature)

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
T
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or

	Please charge Deposit Account No. 10-
	0750/ / the fee of $$180.00$ as set forth
	in §1.17(p).
	In accordance with §1.97(d), this Information
	Disclosure Statement is being filed after the mailing date of
	either a Final Action under §1.113 or a Notice of Allowance
	under §1.311 but before the payment of the Issue Fee.
	Applicant(s) hereby petition(s) for consideration of this
	Information Disclosure Statement. Included are: Statement in
	Accordance with §1.97(e) as set forth below and the fee of
	\$180.00 as set forth in §1.17(p).
	☐ Copies of each of the references listed on the
•	_
,	attached Form PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTO-
	1449 are enclosed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
	Copies of only foreign patent documents and non-
	patent literature are enclosed in accordance with 37 CFR 1.98
	(a)(2). (The U.S. patents and each U.S. patent application
	publication listed on the attached Form PTO-1449 are not
	enclosed because this U.S. patent application was filed after
	June 30 2003 or this international application has entered the

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language can be found in an attached English-language Abstract, English-language equivalent, or complete English language translation.

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D: U.S. Serial No. 10/607,766 filed June 27, 2003 (Atty. Docket No. MCP-5014 NP)

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/MCP5016NP/MGM. This form is submitted in triplicate.

Respectfully submitted,

Michele (Mangini Reg. No. 36,806

Attorney For Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2810
DATED: September 26,2003



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Collection of information diffess it displays	a Talia OND CONDO MUNICEI.
Application Number	10/608,681
Filing Date	June 27, 2003
First Named Inventor	David Wynn et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	MCP-5016 NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		USP 23, (1995) <1216> p. 1981	
		USP 24, 2000 Version, 19-20 and 856-857 (1999)	
		LIEBERMAN, ET AL., Pharmaceutical Dosage Forms, Volume 3, pp.138-150 (1990)	
		LACHMAN ET AL., The Theory and Practice of Industrial Pharmacy, Chapter 11, pp. 293-345 (3 rd Ed. 1986)	
		LIEBERMAN ET AL., Pharmaceutical Dosage Forms - Tablets, Volume 2, 2 nd ed., Marcel Dekker Inc., 1990, pp. 213-217, 327-329	
			-
			<u> </u>
			1

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

SEP 2 6 2003

SE

PTO/SBr/8A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of findination driess it displays a valid OMB control number.					
Application Number	10/608,681				
Filing Date	June 27, 2003				
First Named Inventor	David Wynn et al.				
Group Art Unit					
Examiner Name					
Attorney Docket Number	MCP-5016 NP				

U.S. PATENT DOCUMENTS

		U.S. Patent Doo	ument			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		4,818,539		Shaw et al.	4-04-1989	
	4,851,226		Julian et al.	7-25-1989		
		4,882,154		Yang et al.	11-21-1989	
	4,906,478		Valentine et al.	3-06-1990		
		5,075,114 5,275,822 5,336,486 5,489,436		Roche	12-24-1991	
				Valentine et al.	1-04-1994	
				Acharya	8-09-1994	
				Hoy et al.	2-06-1996	
	6,103,260 6,432,442		Luber et al	8-15-2000		
			Buehler et al.	8-13-2002		
		6,471,991		Robinson et al.	10-29-2002	
		5,989,534		Samain	11-23-1999	

FOREIGN PATENT DOCUMENTS

	Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant			
Examiner Initials	Cite No.1	Office ³	Number⁴ Kir	ndCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	88/06893	A1	Benzon Pharma A/S	Sept. 22, 1988		
		wo	00/30617	A1	Cima Labs Inc.	June 2, 2000		
		JP	5306229		Lederle Japan Ltd. (with complete English Translation)	Nov. 19, 1993		
		JP	P200-95710	Α	Taisho Seiyaku K.K. (English Translation Only)	April 4, 1990		
		wo	95/02391	A1	L'Oreal (See English-Language equivalent U.S. 5,989,534)	Jan. 26, 1995		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SUBMISSION UNDER MPEP 609 D

Application Number	10/608,681
Filing Date	June 27, 2003
First Named Inventor	David Wynn et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	MCP-5016 NP

		rage rorr							
		U.S. P			UMENTS				
			U	U.S. Patent Document					
Examiner	ner Cite Name of Patentee or Applicant				Kin	Pages, Colum where relevant p	ns, Lines,		
Initials	No.1	of Cited Document	l N	Number					s appear
	NO.						,	 	
 								ļ	
								ł	
<u> </u>									
					·				
									
<u> </u>			\dashv						
	 								
	 -						 	 -	
L	<u></u>	FOREIG	N PATE	NT F	OCUME	NTS	<u> </u>	<u> </u>	
		T OKEIO			ent Docum		Pages	Columns, Lines,	
į.		Name of Patentee or	101016	girra	citt Docum	icii.	where r	elevant passages	;
Examiner	Cite	Applicant of Cited Document	Office	3	Number ⁴	KindCode ⁵	or relevant figures appear		T⁵
Initials	No.1		Office	; ——,	Number	NindCode	L	арреат	
	1								Į
			 	$\neg \neg$					
			-	-		-			
		 	†						
ļ		 	├				 		
	<u> </u>	<u> </u>							
]			- 1					
		OTHER PRIOR ART - N	ON PAT	ENT I	TERATU	RE DOCUMEN	ITS		
		Include name of the author (in C	APITO	L LET	TERS), t	itle of the arti	cle (when	appropriate),	
Examiner	Cite	title of the item (book, magazine	title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published				late, page(s),	T ²	
's Initials*	No.1	volume-issue number(s					shed		
ITIMAIS	 	Application of U.S. Serial No. 10/607,70	66 filed J	June 2	7, 2003 (A	tty Docket MCF	-5014 NP)	
									ļ
 	 								
ļ		 							
									

Examiner	Date	,
Signature	Considered	
		